logo
Plus   Neg
Share
Email

Ariad Stops Phase 3 Epic Trial Of Iclusig In Patients With Newly Diagnosed CML

Ariad Pharmaceuticals Inc. (ARIA) announced Friday that it is discontinuing the Phase 3 EPIC or Evaluation of Ponatinib versus Imatinib in Chronic Myeloid Leukemia trial of Iclusig (ponatinib) in patients with newly diagnosed chronic myeloid leukemia. The company said the decision was made in the interest of patient safety based on a recent assessment of data in the clinical trial.

Ariad and the U.S. Food and Drug Administration mutually agreed that the trial should be terminated because arterial thrombotic events were observed in patients treated with Iclusig.

"Our decision to stop the EPIC trial at this time is based on our current evaluation of the safety data in the trial since it was placed on partial clinical hold last week,"stated Timothy Clackson, president of research and development and chief scientific officer at ARIAD.

The company noted that patients in the EPIC trial are being removed from treatment and will be transferred to the care of their physician.

The company announced in early September that fifty percent of patients, or approximately 264 patients, had been enrolled in the EPIC trial by that time. Final enrollment is 307 patients.

Iclusig is commercially available in the U.S. and EU for patients with resistant or intolerant CML and Philadelphia-chromosome positive acute lymphoblastic leukemia.

The company stated that it continues to work with health authorities to make appropriate changes to the Iclusig product labeling to reflect the recently announced safety findings from the pivotal PACE trial that was the basis of its marketing approvals.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Polaris Industries Inc. is recalling certain Ranger and General Utility, as well as All-Terrain vehicles citing risks of crash, the U.S. Consumer Product Safety Commission said in a statement. The Medina, Minnesota-based company has called back about 26,730 units of Model Year 2019 - 2020 Ranger XP 1000 & Model Year 2020 General XP 1000 Utility vehicles. Gilead Sciences Inc. (GILD) said Friday that the European Commission has granted conditional marketing authorization for Veklury or remdesivir as a treatment for SARS-CoV-2 infection, the virus that causes COVID-19. FedEx is asking NFL team Washington Redskins to change its name for its racist connotations. The delivery services company, which is a major sponsor for the team, made the suggestion following increasing pressure from its investors amid the ongoing protests against racial injustice and inequality that arose from the killing of African-American George Floyd.
Follow RTT